31 Mar Wacker
Wacker Biotech is the all-in-one CDMO partner of choice for advanced nucleic acid-based therapies. We enable customers to advance their biologics across the full manufacturing chain, from plasmid DNA (pDNA) as a starting point to the IVT of mRNA to LNP formulation. Our diverse solutions range from pDNA supply using our PLASMITEC® platform, to process development, transfer of mRNA-based processes, R&D production at small scale, and larger-scale GMP manufacturing for clinical and commercial supply. Additionally, customers benefit from a broad spectrum of LNP formulations for their mRNA-based product. In June 2024, we opened a state-of-the-art mRNA competence center in Halle, Germany, which effectively quadruples our mRNA production capacity. This complements existing capabilities at our global GMP facilities in Amsterdam, Halle and San Diego. Also complementing these sites is a dedicated R&D center in Munich, Germany with scientific experts leading innovations in pDNA manufacturing, mRNA production, LNP formulation, and analytical development. Wacker Biotech GmbH, Wacker Biotech B.V. and Wacker Biotech US Inc. are wholly owned subsidiaries of 110-year-old Wacker Chemie AG and also specialize in producing recombinant proteins based on microbial systems and Live Biotherapeutic Products.
